An indirect comparison of intravenous and subcutaneous belimumab efficacy in patients with SLE and high disease activity
{{output}}
Aim: To compare the efficacy of intravenous (IV) and subcutaneous (SC) belimumab plus standard therapy in patients with active, autoantibody-positive systemic lupus erythematosus and high disease activity (HDA). ... ...
